Harbour BioMed (HBM), a global clinical-stage biopharmaceutical company announced that it has entered into a strategic collaboration with Vir Biotechnology (Nasdaq: VIR), a clinical-stage immunology company, to discover, develop and commercialize potential novel therapeutic molecules in the fields of Immuno-Oncology and infectious diseases. HBM will leverage its tools in next-generation technologies including its transgenic Harbour Mice® platforms to generate antibodies for the collaboration. Both parties will then combine their expertise in basic science to accelerate the development of these innovative immunotherapies into the clinic studies for patients suffering from cancers and infectious diseases. "We are excited to join hands with Vir as both companies share a common mission to serve patients' unmet needs," said Dr. Jingsong Wang, the Founder, Chairman, and CEO of Harbour BioMed. "This collaborative partnership harbors big potential for both companies, as we exploit similar underlying immune mechanisms that likely play a critical role in fighting cancers as well as infectious diseases."
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!